 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || BIIB061 / Biogen
Trial completion date, Trial primary completion date: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - Nov 25, 2020
P2, N=300, Not yet recruiting, Sponsor: Biogen
Trial completion date: Jul 2023 --> Sep 2024 | Trial primary completion date: Jul 2023 --> Sep 2024
- || Remyielination!!!?? #BIIB061 #opicinumab @biogen #elezanumab @AbbVieUS #CNMAu8 @CleneNano #Inception5 @Roche @genentech (Twitter) - Sep 8, 2020
- ||| BIIB061 / Biogen
Trial completion date, Trial initiation date, Trial primary completion date: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - Jul 7, 2020
P2, N=300, Not yet recruiting, Sponsor: Biogen
Trial completion date: Jul 2023 --> Sep 2024 | Trial primary completion date: Jul 2023 --> Sep 2024 Trial completion date: Oct 2022 --> Jul 2023 | Initiation date: Jun 2020 --> Sep 2020 | Trial primary completion date: Oct 2022 --> Jul 2023
- ||| BIIB061 / Biogen
Trial initiation date: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - Jan 22, 2020
P2, N=300, Not yet recruiting, Sponsor: Biogen
Trial completion date: Oct 2022 --> Jul 2023 | Initiation date: Jun 2020 --> Sep 2020 | Trial primary completion date: Oct 2022 --> Jul 2023 Initiation date: Dec 2019 --> Jun 2020
- | BIIB061 / Biogen
Trial primary completion date: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - Oct 4, 2019
P2, N=300, Not yet recruiting, Sponsor: Biogen
Initiation date: Dec 2019 --> Jun 2020 Trial primary completion date: May 2022 --> Oct 2022
- | BIIB061 / Biogen
New P2 trial: Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS) (clinicaltrials.gov) - Sep 6, 2019
P2, N=300, Not yet recruiting, Sponsor: Biogen
- ||| BIIB061 / Biogen
Trial completion: Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers (clinicaltrials.gov) - Jun 15, 2016
P1, N=56, Completed, Sponsor: Biogen
Trial primary completion date: May 2022 --> Oct 2022 Active, not recruiting --> Completed
- || BIIB061 / Biogen
Enrollment closed, Enrollment change, Trial primary completion date: Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers (clinicaltrials.gov) - Jan 25, 2016
P1, N=56, Active, not recruiting, Sponsor: Biogen
Active, not recruiting --> Completed Completed --> Active, not recruiting | N=40 --> 56 | Trial primary completion date: Jun 2015 --> May 2016
- BIIB061 / Biogen
Trial completion: Single-Dose Study of a New Formulation of BIIB061 (clinicaltrials.gov) - Sep 11, 2015
P1, N=8, Completed, Sponsor: Biogen
Completed --> Active, not recruiting | N=40 --> 56 | Trial primary completion date: Jun 2015 --> May 2016 Active, not recruiting --> Completed
- | BIIB061 / Biogen
Trial completion: Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers (clinicaltrials.gov) - Sep 8, 2015
P1, N=40, Completed, Sponsor: Biogen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- BIIB061 / Biogen
New P1 trial: Single-Dose Study of a New Formulation of BIIB061 (clinicaltrials.gov) - Aug 13, 2015
P1, N=8, Active, not recruiting, Sponsor: Biogen
- BIIB061 / Biogen
Enrollment closed: Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers (clinicaltrials.gov) - Apr 16, 2015
P1, N=40, Active, not recruiting, Sponsor: Biogen Idec
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- BIIB061 / Biogen
Enrollment open: Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers (clinicaltrials.gov) - Nov 4, 2014
P1, N=40, Recruiting, Sponsor: Biogen Idec
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | BIIB061 / Biogen
Trial completion: Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect (clinicaltrials.gov) - Oct 11, 2014
P1, N=40, Completed, Sponsor: Biogen Idec
Not yet recruiting --> Recruiting Recruiting --> Completed
- | BIIB061 / Biogen
New P1 trial: Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers (clinicaltrials.gov) - Aug 29, 2014
P1, N=40, Not yet recruiting, Sponsor: Biogen Idec
- | BIIB061 / Biogen
New P1 trial: Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect (clinicaltrials.gov) - Feb 23, 2014
P1, N=40, Recruiting, Sponsor: Biogen Idec